Color adaptive therapeutic light control system
US-9205277-B2 · Dec 8, 2015 · US
US10357663B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10357663-B2 |
| Application number | US-201013265591-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 15, 2010 |
| Priority date | Apr 24, 2009 |
| Publication date | Jul 23, 2019 |
| Grant date | Jul 23, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Light therapy is provided to a subject using a system and/or method. The light therapy includes the administration of electromagnetic radiation to the eyeball of the subject underneath the eyelid of the subject while the eyelid of the subject is closed (e.g., as the subject sleeps). The light therapy algorithm may be designed to impact melatonin and/or serotonin levels within the body of the subject in a therapeutically beneficial manner. For example, the light therapy algorithm may be designed to impact melatonin and/or serotonin levels to treat one or more of a sleep and/or mood disorder (e.g., seasonal affective disorder, non-seasonal depression, Circadian rhythm disruption), or other disorders treatable with control over melatonin and/or serotonin levels in the body.
Opening claim text (preview).
What is claimed is: 1. A method of providing light therapy to a subject, the method comprising: generating visible light between an eyeball and an eyelid of the subject; and delivering the visible light to an eyeball of a subject under the eyelid of the subject while the subject is asleep to impact melatonin and/or serotonin levels according to a light therapy algorithm, wherein delivering visible light to the eyeball of the subject under the eyelid of the subject while the subject is asleep comprises converting the wavelength of visible light that has passed through the eyelid of the subject to a therapeutically beneficial wavelength and delivering the visible light having the therapeutically beneficial wavelength to the eyeball of the subject, wherein delivering the visible light to the eyeball of the subject comprises generating visible light with one or more radiation sources carried by a radiation introduction module installed under the eyelid between the eyelid and the eyeball. 2. The method of claim 1 , wherein generating the visible light between the eyeball and the eyelid of the subject comprises generating the visible light with the one or more radiation sources carried by the radiation introduction module installed under the eyelid between the eyelid and the eyeball. 3. The method of claim 1 , wherein the visible light delivered to the eyeball has a therapeutically beneficial wavelength between 410 nm and 580 nm. 4. The method of claim 1 , wherein delivering visible light to the eyeball of the subject under the eyelid of the subject while the subject is asleep is performed at least in part by a lens that sits on the eyeball of the subject, and wherein the lens is configured to selectively block visible light within a predetermined range of wavelengths from reaching the eyeball of the subject if the eyelid of the subject is open. 5. The method of claim 1 , wherein delivering visible light according to a light therapy algorithm includes controlling one or more of an intensity, a flux, a timing, a duration, a pulse frequency, a pulse width, an illumination direction, an illumination pattern, or a subtended angle of illumination of the electromagnetic radiation. 6. A system configured to provide light therapy to a subject, the system comprising: a radiation introduction module configured to rest under an eyelid between an eyeball and the eyelid of a subject during use, wherein the radiation introduction module is configured to, while under the eyelid, generate visible light between the eyeball and the eyelid of the subject and deliver the visible light to the eyeball of the subject under the eyelid of the subject while the subject is asleep to provide light therapy to the subject, wherein the radiation introduction module is configured to receive visible light that has passed through the eyelid of the subject, to convert the wavelength of the received visible light to a therapeutically beneficial wavelength, and to deliver the visible light having the therapeutically beneficial wavelength to the eyeball of the subject; and a processor configured to control introduction of the visible light to the eyeball of the subject to impact melatonin and/or serotonin levels according to a light therapy algorithm, wherein controlling the introduction of the visible light according to the light therapy algorithm includes controlling an intensity of the visible light, and wherein controlling the intensity comprises ramping an illuminance of the visible light in accordance with a sigmoid intensity progression. 7. The method of claim 5 , wherein delivering visible light according to the light therapy algorithm includes controlling the intensity, and wherein controlling the intensity comprises ramping an illuminance of the visible light in accordance with a sigmoid intensity progression. 8. The system of claim 6 , further comprising one or more radiation sources carried by the radiation introduction module between the eyeball and the eyelid of the subject if the radiation introduction module is installed in the eye of the subject and the subject is asleep, and wherein the one or more radiation sources are powered to emit the visible light delivered to the eyeball of the subject by the radiation introduction module. 9. The system of claim 6 , wherein the visible light delivered to the eyeball has a therapeutically beneficial wavelength between 410 nm and 580 nm. 10. The system of claim 6 , wherein the radiation introduction module comprises a lens that sits on the eyeball of the subject, and wherein the lens is configured to selectively block visible light within a predetermined range of wavelengths from reaching the eyeball of the subject if the eyelid of the subject is open.
Psychological treatment · CPC title
Diodes · CPC title
the light being directed to the eyes · CPC title
Visible light · CPC title
Organic light emitting diodes · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.